Doug is a trained lawyer with 25-years of experience working on pharmaceutical issues in Canada, including international trade, IP policy, antitrust law and pricing and reimbursement .
The reality of US MFN policies falls far short of the rhetoric. We cut through the noise to show why near-term impacts in Canada will be limited, and where the real policy risks and opportunities lie.
Despite the recent passing of legislation of the same name by the Trudeau government, national pharmacare remains as fanciful a prospect in Canada as high-speed rail.
